Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

IGC Pharma (IGC) Accumulated Depreciation & Amortization (2016 - 2025)

IGC Pharma has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $1.7 million for Q3 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 33.99% to $1.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2025, down 33.99% year-over-year, with the annual reading at $2.7 million for FY2025, 10.28% up from the prior year.
  • Accumulated Depreciation & Amortization was $1.7 million for Q3 2025 at IGC Pharma, down from $2.8 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $3.3 million in Q4 2021 and troughed at $1.7 million in Q3 2025.
  • The 5-year median for Accumulated Depreciation & Amortization is $2.6 million (2024), against an average of $2.5 million.
  • Year-over-year, Accumulated Depreciation & Amortization plummeted 45.82% in 2022 and then skyrocketed 30.15% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.3 million in 2021, then crashed by 45.82% to $1.8 million in 2022, then skyrocketed by 30.15% to $2.3 million in 2023, then rose by 11.77% to $2.6 million in 2024, then tumbled by 34.22% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Accumulated Depreciation & Amortization are $1.7 million (Q3 2025), $2.8 million (Q2 2025), and $2.7 million (Q1 2025).